Logo image
Back
Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma
Journal article   Open access   Peer reviewed

Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma

Arjun Lakshman, Preet Paul Singh, S Vincent Rajkumar, Angela Dispenzieri, Martha Q Lacy, Morie A Gertz, Francis K Buadi, David Dingli, Yi Lisa Hwa, Amie L Fonder, …
American journal of hematology, v 93(2), pp 179-186
Feb 2018
DOI: https://doi.org/10.1002/ajh.24954
PMID: 29067723
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1002/ajh.24954View
Published, Version of Record (VoR) Restricted

Abstract

Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cisplatin - therapeutic use Cyclophosphamide - therapeutic use Doxorubicin - therapeutic use Etoposide - therapeutic use Humans Middle Aged Multiple Myeloma - drug therapy Multiple Myeloma - mortality Multiple Myeloma - therapy Salvage Therapy - methods Stem Cell Transplantation Survival Analysis Thalidomide Treatment Outcome Vincristine
Experience with intensive chemotherapy for relapsed/refractory multiple myeloma (RRMM) using VDT PACE regimen and its modifications (VDT PACE-like regimens: VPLRs) outside TOTAL THERAPY trials is limited. We analyzed the outcomes of 141 patients with RRMM who received VPLRs at our center between 2006 and 2017 in an intent-to-treat analysis. Median age was 59.7 years and 66.7% of patients were male. A median of 2.2 years (range 0.02-11.4) separated diagnosis of myeloma and inititation of VPLR. High-risk cytogenetics were present in 52.4% patients. Patients received a median of 4 (range 1-14) prior therapies, including stem cell transplant (SCT) in 66.7% patients. Ninety-five (67.4%) patients received VDT PACE, 20 (14.2%) patients received VD PACE and 26 (18.4%) patients received other VPLRs. Patients received a median of 1 cycle (range 1-9) of VPLR. We observed ≥ minimal response in 68.4%, ≥ partial response (PR) in 54.4% and ≥ very good PR in 10.3% patients. Median progression-free survival was 3.1 months (95% CI, 1.9-3.9) and median overall survival (OS) was 8.1 months (CI, 6.2-9.9). One-hundred and sixteen (82.3%) patients received some therapy after VPLR; 71 (61.2%) received systemic chemotherapy, while 45 (38.8%) underwent SCT. Median OS for those who received SCT after VPLR was 15.1 months (CI, 10.3-20.8). Age ≥ 60 years (hazard ratio [HR] 2.3 [CI, 1.4-3.7]; P = 0.0008) and R-ISS III stage (HR- 2.4 [CI, 1.3-4.0]; P = 0.003) predicted shorter OS in patients receiving VPLR. VPLRs are effective in heavily pre-treated RRMM. In fit patients, SCT can be used to consolidate the response to VPLR.

Metrics

6 Record Views
60 citations in Web of Science
57 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Hematology
Logo image